|
||||||
|
||||||
|
|
|
| Essential Reading Living with TED: My Race from Patient to Advocate Once regarded as the “fastest woman in the world,” Gail Devers writes about how Graves’ disease and associated thyroid eye disease (TED) impacted her career. Devers stresses the importance of early diagnosis for TED, as well as how physicians need to proactively educate Graves’ patients on their higher likelihood of developing TED. Link Ben LaHood: Power List Perspectives Ophthalmologists from this year’s Power List look at the major trends impacting the industry today – and offer predictions for the future. In this installment, Ben LaHood, cataract and refractive surgeon at Adelaide Eye and Laser Centre, considers how machine learning might impact ophthalmology, as well as how our focus on postoperative enhancements to cataract surgery might just become the new norm. Link |
|
|
|
GA measurements comparison Researchers from the University of Wisconsin School of Medicine and Public Health have compared geographic atrophy (GA) measurements in age-related macular degeneration using standard blue-light autofluorescence (FAF) from Heidelberg Spectralis and green-light ultrawide field (UWF) FAF from Optos. They found that GA measurements were slightly larger in standard blue-light FAF, although both methods tracked similar GA progression rates over time. The findings suggest that, though either modality may be used longitudinally in clinical settings, they should not be used interchangeably. Link Retinal function and MS A team from the University Hospital Zurich and University of Zurich used electroretinography (ERG) to assess retinal function in individuals with advanced multiple sclerosis (MS). Compared with controls, MS patients show delays in specific ERG responses, indicating retinal bipolar cell dysfunction. However, this does not vary significantly with disease severity, duration, or history of optic neuritis, limiting ERG’s utility as a biomarker for monitoring or predicting disease progression. Link
Are you a member of ARVO? Would you like to share your professional highlights, experiences, and the importance of ARVO to your career successes?
Please email edit@theophthalmologist.com.
|
| Also in the News... New GA treatment. PulseSight Therapeutics, a clinical-stage biotech company, recently presented new data on its new geographic atrophy (GA) treatment, PS-611, at the EVER Congress 2024 held in Valencia, Spain. The company plans to submit a phase I clinical trial authorization (CTA) by the end of the year, followed by a phase II proof-of-concept trial by the end of 2027. Link
Diabetes-related Eye Disease Awareness Month. The US’ leading volunteer eye health organization, Prevent Blindness, has announced that November will be “Diabetes-related Eye Disease Awareness Month.” As part of the event, it will offer free resources to the public, including fact sheets and educational videos. Link
Biodegradable implant for glaucoma drug delivery. PolyActiva, a clinical-stage company aiming to provide long-term drug delivery options for glaucoma patients, has presented promising new clinical data from its phase II trial of PA5108 – a biodegradable drug-releasing implant. Link
Clocking POAG progression. Using epigenetic clocks to assess the biological age of 200 primary open-angle glaucoma (POAG) patients, a medRxiv study has found that accelerated epigenetic aging is significantly linked to faster POAG progression, with each additional year of biological age increasing the likelihood of rapid disease progression by 15 percent. The findings support the potential of using epigenetic age as a biomarker for glaucoma and exploring treatments targeting age-related mechanisms to slow disease progression. Link |
| Digital Events View our Webinar Hub |
